Show simple item record

Evolving a national clinical trials learning health system

dc.contributor.authorStensland, Kristian D.
dc.contributor.authorRichesson, Rachel L.
dc.contributor.authorVince, Randy A.
dc.contributor.authorSkolarus, Ted A.
dc.contributor.authorSales, Anne E.
dc.date.accessioned2023-05-01T19:12:58Z
dc.date.available2024-05-01 15:12:56en
dc.date.available2023-05-01T19:12:58Z
dc.date.issued2023-04
dc.identifier.citationStensland, Kristian D.; Richesson, Rachel L.; Vince, Randy A.; Skolarus, Ted A.; Sales, Anne E. (2023). "Evolving a national clinical trials learning health system." Learning Health Systems 7(2): n/a-n/a.
dc.identifier.issn2379-6146
dc.identifier.issn2379-6146
dc.identifier.urihttps://hdl.handle.net/2027.42/176322
dc.description.abstractClinical trials generate key evidence to inform decision making, and also benefit participants directly. However, clinical trials frequently fail, often struggle to enroll participants, and are expensive. Part of the problem with trial conduct may be the disconnected nature of clinical trials, preventing rapid data sharing, generation of insights and targeted improvement interventions, and identification of knowledge gaps. In other areas of healthcare, a learning health system (LHS) has been proposed as a model to facilitate continuous learning and improvement. We propose that an LHS approach could greatly benefit clinical trials, allowing for continuous improvements to trial conduct and efficiency. A robust trial data sharing system, continuous analysis of trial enrollment and other success metrics, and development of targeted trial improvement interventions are potentially key components of a Trials LHS reflecting the learning cycle and allowing for continuous trial improvement. Through the development and use of a Trials LHS, clinical trials could be treated as a system, producing benefits to patients, advancing care, and decreasing costs for stakeholders.
dc.publisherNational Academies Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherlearning health system
dc.subject.otherlearning cycle
dc.subject.othercontinuous improvement
dc.subject.otherclinical trials
dc.titleEvolving a national clinical trials learning health system
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelBiomedical Health Sciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176322/1/lrh210327.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176322/2/lrh210327_am.pdf
dc.identifier.doi10.1002/lrh2.10327
dc.identifier.sourceLearning Health Systems
dc.identifier.citedreferenceDuma N, Vera Aguilera J, Paludo J, et al. Representation of minorities and women in oncology clinical trials: review of the past 14 years. JOP. 2018; 14: e1 - e10.
dc.identifier.citedreferenceElliott JH, Synnot A, Turner T, et al. Living systematic review: 1. Introduction—the why, what, when, and how. J Clin Epidemiol. 2017; 91: 23 - 30.
dc.identifier.citedreferenceHopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009; 2009 ( 1 ): MR000006. doi: 10.1002/14651858.MR000006.pub3
dc.identifier.citedreferenceWouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020; 323: 844 - 853.
dc.identifier.citedreferenceStensland KD, Malinconico L, Canes D. Tamsulosin and distal ureteral stones-how much evidence is enough? Exploring value of information in urology. J Urol. 2019; 202: 465 - 466.
dc.identifier.citedreferenceSoni PD, Hartman HE, Dess RT, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol. 2019; 37: 1209 - 1216.
dc.identifier.citedreferencePrasad V. Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms? Eur J Clin Invest. 2021; 51: e13580. doi: 10.1111/eci.13580
dc.identifier.citedreferenceUS FDA. Framework for FDA’s Real-World Evidence Program. 2018. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed 23 May, 2022.
dc.identifier.citedreferenceCurtis JR, Foster PJ, Saag KG. Tools and methods for real-world evidence generation: pragmatic trials, electronic consent, and data linkages. Rheum Dis Clin North Am. 2019; 45: 275 - 289.
dc.identifier.citedreferenceLedford H. Millions of black people affected by racial bias in health-care algorithms. Nature. 2019; 574: 608 - 609.
dc.identifier.citedreferenceUnger JM, Moseley AB, Cheung CK, et al. Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. JCO. 2021; 39: 1339 - 1348.
dc.identifier.citedreferenceMeyer S, Woldu HG, Sheets LR. Sociodemographic diversity in cancer clinical trials: new findings on the effect of race and ethnicity. Contemp Clin Trials Commun. 2021; 21: 100718.
dc.identifier.citedreferenceWoodward EN, Singh RS, Ndebele-Ngwenya P, Melgar Castillo A, Dickson KS, Kirchner JAE. A more practical guide to incorporating health equity domains in implementation determinant frameworks. Implement Sci Commun. 2021; 2: 61.
dc.identifier.citedreferenceWoodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JAE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci. 2019; 14: 26.
dc.identifier.citedreferencePoola AS, Oyetunji TA, Holcomb GW, St Peter SD. Maturation of effect size during enrollment of prospective randomized trials. J Surg Res. 2018; 223: 34 - 38.
dc.identifier.citedreferenceZarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov—the final rule. N Engl J Med. 2016; 375: 1998 - 2004.
dc.identifier.citedreferenceAnderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 2015; 372: 1031 - 1039.
dc.identifier.citedreferenceBecker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in ClinicalTrials.gov and high-impact journals. JAMA. 2014; 311: 1063 - 1065.
dc.identifier.citedreferenceMeeker-O’Connell A, Sam LM, Bergamo N, Little JA. TransCelerate’s clinical quality management system: from a vision to a conceptual framework. Ther Innov Regul Sci. 2016; 50: 397 - 413.
dc.identifier.citedreferenceYamatani Y, Saeki H, Tanaka R, Komeda T, Watabe Y, Sakai H. How many clinical trials exist that have adopted selective safety data collection? NEJM literature search results: the possibility of harmonizing the ICH E19 guideline. Ther Innov Regul Sci. 2022; 56: 677 - 684.
dc.identifier.citedreferenceKang M, Kendall MA, Ribaudo H, et al. Incorporating estimands into clinical trial statistical analysis plans. Clin Trials. 2022; 19 ( 3 ): 285 - 291.
dc.identifier.citedreferenceVisweswaran S, Becich MJ, D’Itri VS, et al. Accrual to clinical trials (ACT): a clinical and translational science award consortium network. JAMIA Open. 2018; 1: 147 - 152.
dc.identifier.citedreferenceJones WS, Wruck LM, Harrington RA, Hernandez AF. Iterative approaches to the use of electronic health records data for large pragmatic studies. Contemp Clin Trials. 2022; 117: 106789.
dc.identifier.citedreferenceNational Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, et al. Innovation in cancer care and cancer research in the context of the COVID-19 pandemic. Paper presented at: Proceedings of a Workshop [Internet]. Washington DC: National Academies Press; 2022. https://www.nap.edu/catalog/26470. Accessed May 23, 2022.
dc.identifier.citedreferenceDenburg A, Rodriguez-Galindo C, Joffe S. Clinical trials infrastructure as a quality improvement intervention in low- and middle-income countries. Am J Bioeth. 2016; 16: 3 - 11.
dc.identifier.citedreferenceGrand View Research. Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts 2021–2028; 2021. https://www.grandviewresearch.com/industry-analysis/global-clinical-trials-market. Accessed 30 July, 2021.
dc.identifier.citedreferenceKhunger M, Rakshit S, Hernandez AV, et al. Premature clinical trial discontinuation in the era of immune checkpoint inhibitors. Oncologist. 2018; 23: 1494 - 1499.
dc.identifier.citedreferenceStensland KD, McBride RB, Latif A, et al. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst. 2014; 106.
dc.identifier.citedreferenceStensland K, Kaffenberger S, Canes D, Galsky M, Skolarus T, Moinzadeh A. Assessing genitourinary cancer clinical trial accrual sufficiency using archived trial data. JCO Clin Cancer Inform. 2020; 4: 614 - 622.
dc.identifier.citedreferenceMurthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720.
dc.identifier.citedreferenceMoore TJ, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med. 2018; 178: 1451 - 1457.
dc.identifier.citedreferenceHilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Intern Med. 2020; 180: 1108 - 1115.
dc.identifier.citedreferenceTreweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018; 2: MR000013.
dc.identifier.citedreferenceKim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of cancer research joint research statement. J Clin Oncol. 2017; 35: 3737 - 3744.
dc.identifier.citedreferenceForum on Drug Discovery, Development, and Translation, Forum on Neuroscience and Nervous System Disorders, National Cancer Policy Forum et al. Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward: Proceedings of a Workshop. Washington, D.C.: National Academies Press; 2020. https://www.nap.edu/catalog/25838. Accessed May 23, 2022
dc.identifier.citedreferenceFriedman CP, Rubin JC, Sullivan KJ. Toward an information infrastructure for Global Health improvement. Yearb Med Inform. 2017; 26: 16 - 23.
dc.identifier.citedreferenceKraft S, Caplan W, Trowbridge E, et al. Building the learning health system: describing an organizational infrastructure to support continuous learning. Learn Health Syst. 2017; 1: e10034.
dc.identifier.citedreferenceForum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division et al. Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop. Washington, D.C.: National Academies Press; 2022 https://www.nap.edu/catalog/26349. Accessed May 11, 2022
dc.identifier.citedreferenceBibbins-Domingo K, Helman A, Dzau VJ. The imperative for diversity and inclusion in clinical trials and health research participation. JAMA. 2022; 327: 2283.
dc.identifier.citedreferenceKim ES, Uldrick TS, Schenkel C, et al. Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO–friends of cancer research joint research statement. Clin Cancer Res. 2021; 27: 2394 - 2399.
dc.identifier.citedreferenceSpira AI, Stewart MD, Jones S, et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research laboratory reference ranges and testing intervals work group. Clin Cancer Res. 2021; 27: 2416 - 2423.
dc.identifier.citedreferenceRoss JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM. Time to publication among completed clinical trials. JAMA Intern Med. 2013; 173: 825 - 828.
dc.identifier.citedreferenceTuzzio L, Larson EB. The promise of pragmatic clinical trials embedded in learning health systems. eGEMS. 2019; 7: 10.
dc.identifier.citedreferenceRamsberg J, Platt R. Opportunities and barriers for pragmatic embedded trials: triumphs and tribulations. Learn Health Sys. 2018; 2: e10044.
dc.identifier.citedreferencePowell GA, Bonnett LJ, Smith CT, Hughes DA, Williamson PR, Marson AG. Using routinely recorded data in a UKRCT: a comparison to standard prospective data collection methods. Trials. 2021; 22: 429.
dc.identifier.citedreferenceRogers JR, Lee J, Zhou Z, Cheung YK, Hripcsak G, Weng C. Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review. J Am Med Inform Assoc. 2021; 28: 144 - 154.
dc.identifier.citedreferenceVazquez E, Gouraud H, Naudet F, et al. Characteristics of available studies and dissemination of research using major clinical data sharing platforms. Clin Trials. 2021; 18: 657 - 666.
dc.identifier.citedreferenceZarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database—update and key issues. N Engl J Med. 2011; 364: 852 - 860.
dc.identifier.citedreferenceMagnani CJ, Steinberg JR, Harmange CI, et al. Clinical trial outcomes in urology: assessing early discontinuation, results reporting and publication in ClinicalTrials.Gov registrations 2007–2019. J Urol. 2021; 205: 1159 - 1168.
dc.identifier.citedreferenceGuinn D, Wilhelm EE, Shoulson I. Reasons for premature conclusion of late phase clinical trials: an analysis of ClinicalTrials.Gov registered phase III trials. Ther Innov Regul Sci. 2020; 54: 232 - 239.
dc.identifier.citedreferenceStensland KD, Kaffenberger SD, George AK, et al. Prostate cancer clinical trial completion: the role of geography. Contemp Clin Trials. 2021; 111: 106600.
dc.identifier.citedreferenceCTTI. Clinical Trials Transformation Initiative. 2020; https://www.ctti-clinicaltrials.org.
dc.identifier.citedreferenceSertkaya A, Wong H-H, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016; 13: 117 - 126.
dc.identifier.citedreferenceSchroen AT, Petroni GR, Wang H, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. cooperative oncology groups. Clin Cancer Res. 2012; 18: 256 - 262.
dc.identifier.citedreferenceSkolarus TA, Sales AE. Using implementation science to improve urologic oncology care. Urol Oncol Sem Orig Invest. 2016; 34: 384 - 387.
dc.identifier.citedreferenceDranseika V, Gefenas E, Waligora M. Broadening the “infrastructure effect”: lessons from the early development of research ethics in Eastern Europe. Am J Bioeth. 2016; 16: 26 - 28.
dc.identifier.citedreferenceUnger JM, Hershman DL, Osarogiagbon RU, et al. Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies. JNCI Cancer Spectr. 2020; 4: pkaa034.
dc.identifier.citedreferenceFeyman Y, Provenzano F, David FS. Disparities in clinical trial access across US urban areas. JAMA Netw Open. 2020; 3: e200172.
dc.identifier.citedreferenceHamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control. 2016; 23: 327 - 337.
dc.identifier.citedreferenceUnger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019; 111: 245 - 255.
dc.identifier.citedreferenceLondon AJ, Kimmelman J. Clinical trial portfolios: a critical oversight in human research ethics, drug regulation, and policy. Hastings Cent Rep. 2019; 49: 31 - 41.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.